VIJAY MODUR - 25 Jan 2023 Form 4 Insider Report for Eloxx Pharmaceuticals, Inc.

Role: HEAD OF R&D
Signature: /s/ Sumit Aggarwal, Attorney-in-Fact for Vijay Modur
Issuer symbol: N/A
Transactions as of: 25 Jan 2023
Net transactions value: $0
Form type: 4
Filing time: 27 Jan 2023, 15:02:53 UTC
Previous filing: 03 Dec 2021
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ELOX	Stock Options (Right to Buy)	Award	$0	+30,000		$0.000000	30,000	25 Jan 2023	Common Stock	30,000	$4.27	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The option vests and becomes exercisable as to 25% of the underlying shares on the first anniversary of January 25, 2023, and the remaining 75% of the underlying shares vest in 12 equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer through the applicable vesting date.

Remarks:

On December 1, 2022, the Issuer effected a 1-for-40 reverse stock split. The share counts herein have been adjusted to reflect the reverse stock split.